|Articles|August 1, 2000

New Advances in the Treatment of Type 2 Diabetes: Clinical and Economic Implications for Managed Car
Volume 6
Issue 13 Suppl

The Clinical Implications of Insulin Resistance

Author(s)Anne L Peters, MD

Download PDF: The Clinical Implications of Insulin Resistance

Articles in this issue

almost 26 years ago

Article

Participating Faculty

almost 26 years ago

Article

Introduction

almost 26 years ago

Article

Hyperlipidemia and Cardiovascular Risk Factors in Patients with Type 2 Diabetes

almost 26 years ago

Article

Cost-Effective Management of Type 2 Diabetes: Providing Quality in a Cost-Constrained Environment

almost 26 years ago

Article

Thiazolidiones in the Treatment of Type 2 Diabetes: A Clinician's Perspective

almost 26 years ago

Article

Selected Abstracts

almost 26 years ago

Article

CME/CPE Quiz

almost 26 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

The Clinical Implications of Insulin Resistance

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

Diagnosing Alzheimer's Disease Agitation: Triggers, Care Specialties, and the Role of Primary Care

Defining Alzheimer's Disease Agitation: Diagnostic Criteria, Symptoms, and Disease Course

Nipocalimab Improves gMG Outcomes Across East Asian Subgroup

Contributor: State Leaders Need Real-World Evidence to Integrate Social Care at Scale

FDA Approves First Autoinjector for At-Home IV-Equivalent Diuresis